Combination vectors and methods for treating cancer
AssigneeAmerican Gene Technologies International Inc.
InventorsTyler Lahusen, Mei-Ling Liou, Lingzhi Xiao, Haishan Li, Charles David Pauza
Life of this patent
Estimating the term…
Abstract
A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.
Claims26
A viral vector comprising a therapeutic cargo portion, wherein the therapeutic cargo portion comprises:
- a first small RNA sequence that binds to a first pre-determined complementary FDPS mRNA sequence, thereby inhibiting FDPS expression;
- and
- a second small RNA sequence that binds to a first pre-determined complementary cMyc mRNA sequence, thereby inhibiting cMyc expression,
- wherein the first small RNA sequence comprises a sequence having at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% identity with SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, or SEQ ID NO:
- 4, and
- wherein the second small RNA sequence comprises a sequence having at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% identity with SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, or SEQ ID NO:
- 14.
A viral vector comprising a therapeutic cargo portion, wherein the therapeutic cargo portion comprises:
- a first small RNA sequence that binds to a first pre-determined complementary CD47 mRNA sequence, thereby inhibiting CD47 expression;
- and
- a second small RNA sequence that binds to a first pre-determined complementary cMyc mRNA sequence, thereby inhibiting cMyc expression,
- wherein the first small RNA sequence comprises SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, or SEQ ID NO:
- 9, and
- wherein the second small RNA sequence comprises SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, or SEQ ID NO:
- 14.
A viral vector comprising a therapeutic cargo portion, wherein the therapeutic cargo portion comprises:
- a first small RNA sequence that binds to a first pre-determined complementary FDPS mRNA sequence, thereby inhibiting FDPS expression;
- and
- a second small RNA sequence that binds to a first pre-determined complementary CD47 mRNA sequence, thereby inhibiting CD47 expression, and
- a third small RNA sequence that binds to a first pre-determined complementary cMyc mRNA sequence, thereby inhibiting cMyc expression,
- wherein the first small RNA sequence comprises a sequence having at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% identity with SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, or SEQ ID NO:
- 4, and
- wherein the second small RNA sequence comprises a sequence having at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% identity with SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, or SEQ ID NO:
- 9.
A viral vector comprising a therapeutic cargo portion, wherein the therapeutic cargo portion comprises:
- a first small RNA sequence that binds to a first pre-determined complementary FDPS mRNA sequence, thereby inhibiting FDPS expression;
- and
- a second small RNA sequence that binds to a first pre-determined complementary CD47 mRNA sequence, thereby inhibiting CD47 expression, and
- a third small RNA sequence that binds to a first pre-determined complementary cMyc mRNA sequence, thereby inhibiting cMyc expression,
- wherein the first small RNA sequence comprises a sequence having at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% identity with SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, or SEQ ID NO:
- 4, and
- wherein the third small RNA sequence comprises at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% identity with SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, or SEQ ID NO:
- 14.
A viral vector comprising a therapeutic cargo portion, wherein the therapeutic cargo portion comprises
- a sequence encoding a small RNA, wherein that small RNA is capable of binding to a pre-determined complementary FDPS mRNA sequence, thereby inhibiting FDPS expression,
- wherein the FDPS mRNA sequence comprises at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% identity with SEQ ID NO:
- 49, SEQ ID NO:
- 50, SEQ ID NO:
- 51, or SEQ ID NO:
- 52.
A viral vector comprising a therapeutic cargo portion, wherein the therapeutic cargo portion comprises
- a sequence encoding a small RNA, wherein that small RNA is capable of binding to a pre-determined complementary CD47 mRNA sequence, thereby inhibiting CD47 expression,
- wherein the CD47 mRNA sequence comprises at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% identity with the target sequence of SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 66, SEQ ID NO:
- 67, SEQ ID NO:
- 68, or SEQ ID NO:
- 82.
A viral vector comprising a therapeutic cargo portion, wherein the therapeutic cargo portion comprises
- a first sequence encoding a first small RNA, wherein that first small RNA is capable of binding to a first pre-determined complementary FDPS mRNA sequence, thereby inhibiting FDPS expression;
- and
- a second sequence encoding a second small RNA, wherein that second small RNA is capable of binding to a second pre-determined complementary CD47 mRNA sequence, thereby inhibiting CD47 expression,
- wherein the FDPS mRNA sequence comprises at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% identity with SEQ ID NO:
- 49, SEQ ID NO:
- 50, SEQ ID NO:
- 51, or SEQ ID NO:
- 52, and
- wherein the CD47 mRNA sequence comprises at least about 80%, or at least about 85%, or at least about 90%, or at least about 95% identity with the target sequence of SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 66, SEQ ID NO:
- 67, SEQ ID NO:
- 68, or SEQ ID NO:
- 82.
Dependencies are inferred from the claim text.